U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H7ClN2O2S
Molecular Weight 230.671
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIAZOXIDE

SMILES

CC1=NC2=CC=C(Cl)C=C2S(=O)(=O)N1

InChI

InChIKey=GDLBFKVLRPITMI-UHFFFAOYSA-N
InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

HIDE SMILES / InChI
Molecular Formula C8H7ClN2O2S
Molecular Weight 230.671
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Diazoxide is a drug which was approved by FDA for the treatment of secondary hyperinsulinemia. The drug exerts its action by binding to SUR1 subunit of ATP-sensitive potassium channel that leads to the channel opening.

CNS Activity

CNS Penetrant
2588
Sources: www.ncbi.nlm.nih.gov/pubmed/22056385

Approval Year

1973
95
Targets

Targets

Primary TargetPharmacologyConditionPotency
Opener
34
 10.94 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
PROGLYCEM

Approved Use

Proglycem (ORAL DIAZOXIDE) is useful in the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy in adults. Infants and Children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis.

Launch Date

1976
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
45 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28715810/
2.5 mg 3 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
345 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28715810/
2.5 mg 3 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28715810/
2.5 mg 3 times / day steady-state, oral
dose: 2.5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: MALE
food status: UNKNOWN
30 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
2.5 mg/kg 3 times / day multiple, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
2.5 mg/kg 3 times / day multiple, oral
dose: 2.5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DIAZOXIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, adult + children
Health Status: unhealthy
Age Group: adult + children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Disc. AE: Hyperosmolar (non-ketotic) coma...
AEs leading to
discontinuation/dose reduction:
Hyperosmolar (non-ketotic) coma
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Disc. AE: Diabetic hyperosmolar coma...
AEs leading to
discontinuation/dose reduction:
Diabetic hyperosmolar coma
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Disc. AE: Musculoskeletal and connective tissue deformities of skull, face and buccal cavity...
AEs leading to
discontinuation/dose reduction:
Musculoskeletal and connective tissue deformities of skull, face and buccal cavity (4 patients)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Disc. AE: Cataracts...
AEs leading to
discontinuation/dose reduction:
Cataracts
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
15 mg/kg 1 times / day multiple, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, infant + neonates
Health Status: unhealthy
Age Group: infant + neonates
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Disc. AE: Pulmonary hypertension...
AEs leading to
discontinuation/dose reduction:
Pulmonary hypertension
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Hyperosmolar (non-ketotic) coma Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, adult + children
Health Status: unhealthy
Age Group: adult + children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Diabetic hyperosmolar coma Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Musculoskeletal and connective tissue deformities of skull, face and buccal cavity 4 patients
Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Cataracts Disc. AE
8 mg/kg 1 times / day multiple, oral
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, children
Health Status: unhealthy
Age Group: children
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Pulmonary hypertension Disc. AE
15 mg/kg 1 times / day multiple, oral
Dose: 15 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
unhealthy, infant + neonates
Health Status: unhealthy
Age Group: infant + neonates
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
GLUT2
4

GLUT4
5
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
GLUT2
8
 yes
GLUT4
20
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4495
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4495
ChemicalBook
CB8426893
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8426893
eMolecules
1934615
https://www.emolecules.com/cgi-bin/more?vid=1934615
eMolecules
36757797
https://www.emolecules.com/cgi-bin/more?vid=36757797
MolPort
MolPort-003-666-772
https://www.molport.com/shop/molecule-link/MolPort-003-666-772
MolPort
MolPort-003-941-186
https://www.molport.com/shop/molecule-link/MolPort-003-941-186
ZINC
ZINC000003872277
http://zinc15.docking.org/substances/ZINC000003872277
PubMed

PubMed

TitleDatePubMed
Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection.
2001-11-09
Opening of mitochondrial K(ATP) channels attenuates the ouabain-induced calcium overload in mitochondria.
2001-11-09
Mitochondrial ATP-sensitive channel opener does not induce vascular preconditioning, but potentiates the effect of a preconditioning ischemia on coronary reactive hyperemia in the anesthetized goat.
2001-11
The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
2001-11
Mitochondrial K(ATP) channel as an end effector of cardioprotection during late preconditioning: triggering role of nitric oxide.
2001-11
Management of hyperinsulinemia with diazoxide in an elderly hemodialysis patient.
2001-11
Ischemic and pharmacological preconditioning in Girardi cells and C2C12 myotubes induce mitochondrial uncoupling.
2001-10-26
Glucose effects on gastric motility and tone evoked from the rat dorsal vagal complex.
2001-10-01
The KATP channel opener diazoxide protects cardiac myocytes during metabolic inhibition without causing mitochondrial depolarization or flavoprotein oxidation.
2001-10
Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury.
2001-10
Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice.
2001-10
Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism.
2001-09-21
Identification and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium channel in brain.
2001-09-07
Incorporation of sulfonylurea into N-isopropylacrylamide as an extracellular matrix for an artificial pancreas.
2001-09
Critical timing of mitochondrial K(ATP) channel opening for enhancement of myocardial tolerance against infarction.
2001-09
[Activation of ATP-sensitive K+ channels by ADP and K+ channel openers: homology model of sulfonylurea receptor carboxyl-termini].
2001-09
Lidocaine and mexiletine inhibit mitochondrial oxidation in rat ventricular myocytes.
2001-09
Synthesis and characterization of a quinolinonic compound activating ATP-sensitive K(+) channels in endocrine and smooth muscle tissues.
2001-09
Mitochondrial K(ATP) channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation.
2001-09
Diazoxide induced cardioprotection: what comes first, K(ATP) channels or reactive oxygen species?
2001-09
Contribution of both the sarcolemmal K(ATP) and mitochondrial K(ATP) channels to infarct size limitation by K(ATP) channel openers: differences from preconditioning in the role of sarcolemmal K(ATP) channels.
2001-09
Hyperinsulinism and hyperammonemia syndrome: report of twelve unrelated patients.
2001-09
Hepatothermic therapy of obesity: rationale and an inventory of resources.
2001-09
Mitochondrial K(ATP) channel activation reduces anoxic injury by restoring mitochondrial membrane potential.
2001-09
Amino acids and insulin are both required to regulate assembly of the eIF4E. eIF4G complex in rat skeletal muscle.
2001-09
Effects of bezafibrate on beta-cell function of rat pancreatic islets.
2001-08-31
Modulation of islet ATP content by inhibition or stimulation of the Na(+)/K(+) pump.
2001-08-24
Inhibition of large-conductance calcium-activated potassium channel by 2-methoxyestradiol in cultured vascular endothelial (HUV-EC-C) cells.
2001-08-01
Sulfonylurea receptors inhibit the epithelial sodium channel (ENaC) by reducing surface expression.
2001-08
Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome.
2001-08
Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of beta-oxidation in insulin secretion.
2001-08
ATP-sensitive K+ channels and cellular actions of morphine in periaqueductal gray slices of neonatal and adult rats.
2001-08
Laparoscopic pancreatectomy for persistent hyperinsulinemic hypoglycemia of infancy.
2001-08
Downregulation of protein kinase C inhibits activation of mitochondrial K(ATP) channels by diazoxide.
2001-07-03
Effect on insulin release of compounds structurally related to the potassium-channel opener 7-chloro-3-isopropylamino-4H-1,2,4-benzothiadiazine 1,1-dioxide (BPDZ 73): introduction of heteroatoms on the 3-alkylamino side chain of the benzothiadiazine 1,1-dioxide ring.
2001-07
Intrinsic optical signals in respiratory brain stem regions of mice: neurotransmitters, neuromodulators, and metabolic stress.
2001-07
Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
2001-07
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
2001-06-26
Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells.
2001-06-22
Role of intracellular Na(+) kinetics in preconditioned rat heart.
2001-06-08
Store-operated influx of Ca(2+) in pancreatic beta-cells exhibits graded dependence on the filling of the endoplasmic reticulum.
2001-06
Transient hyperinsulinism in an asphyxiated newborn infant with hypoglycemia.
2001-06
Restoration of Ca2+-inhibited oxidative phosphorylation in cardiac mitochondria by mitochondrial Ca2+ unloading.
2001-04
Interaction of sulfonylurea-conjugated polymer with insulinoma cell line of MIN6 and its effect on insulin secretion.
2001-04
Mitochondrial ATP-sensitive K+ channels play a role in cardioprotection by Na+-H+ exchange inhibition against ischemia/reperfusion injury.
2001-03-01
Failure to precondition pathological human myocardium.
2001-03-01
Disopyramide and its metabolite enhance insulin release from clonal pancreatic beta-cells by blocking K(ATP) channels.
2001-01
Modulation of beta-cell ouabain-sensitive 86Rb+ influx (Na+/K+ pump) by D-glucose, glibenclamide or diazoxide.
2001
Intracellular potassium and chloride channels: an update.
2001
Mitochondrial ATP-sensitive potassium channel plays a dominant role in ischemic preconditioning of rabbit heart.
2001
Patents

Patents

JP2001302543A
3
JPH05255048A
2

Sample Use Guides

In Vivo Use Guide
Adults and children: The usual daily dosage is 3 to 8 mg/kg, divided into two or three equal doses every 8 or 12 hours. Infants and newborns: The usual daily dosage is 8 to 15 mg/kg divided into two or three equal doses every 8 to 12 hours. An appropriate starting dosage is 10 mg/kg/day, divided into three equal doses every 8 hours.
Route of Administration: Oral
In Vitro Use Guide
Diazoxide inhibited glucagon secretion in rat pancreas at concentration of 325 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:50:23 GMT 2025
Edited
by admin
on Mon Mar 31 17:50:23 GMT 2025
Record UNII
O5CB12L4FN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYPERSTAT
Preferred Name English
DIAZOXIDE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
EUDEMINE INJECTION
Common Name English
DIAZOXIDE [EP MONOGRAPH]
Common Name English
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
Systematic Name English
DIAZOXIDE [MI]
Common Name English
SCH-6783
Code English
DIAZOXIDE [ORANGE BOOK]
Common Name English
SCH 6783
Code English
Diazoxide [WHO-DD]
Common Name English
DIAZOXIDE [VANDF]
Common Name English
DIAZOXIDE [USP-RS]
Common Name English
DIAZOXIDE [USP MONOGRAPH]
Common Name English
2H-1,2,4-BENZOTHIADIAZINE, 7-CHLORO-3-METHYL-, 1,1-DIOXIDE
Systematic Name English
HYPERTONALUM
Common Name English
DIAZOXIDE [MART.]
Common Name English
DIAZOXIDE [JAN]
Common Name English
PROGLYCEM
Brand Name English
diazoxide [INN]
Common Name English
DIAZOXIDUM [WHO-IP LATIN]
Common Name English
SRG-95213
Code English
SRG 95213
Code English
NSC-76130
Code English
DIAZOXIDE [WHO-IP]
Common Name English
DIAZOXIDE [USAN]
Common Name English
NSC-64198
Code English
Classification Tree Code System Code
WHO-ATC V03AH01
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
WHO-ATC C02DA01
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
NCI_THESAURUS C29707
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
WHO-VATC QV03AH01
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
WHO-VATC QC02DA01
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
FDA ORPHAN DRUG 383712
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
Code System Code Type Description
MERCK INDEX
m4277
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY Merck Index
EPA CompTox
DTXSID7022914
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DIAZOXIDE
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY Description: A white, or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water and ether R; freely soluble in dimethylformamide R; slightly soluble in ethanol (~750 g/l) TS. Category: Antihypertensive. Storage: Diazoxide should be kept in a well-closed container. Definition: Diazoxide contains not less than 98.0% and not more than 101.0% of C8H7ClN2O2S, calculated with reference to thedried substance.
INN
1294
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-668-1
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
MESH
D003981
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
DRUG BANK
DB01119
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
RXCUI
3327
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY RxNorm
RS_ITEM_NUM
1186000
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
DRUG CENTRAL
854
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
DAILYMED
O5CB12L4FN
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
SMS_ID
100000092606
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
CAS
364-98-7
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
PUBCHEM
3019
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
IUPHAR
2409
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
ChEMBL
CHEMBL181
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
WIKIPEDIA
DIAZOXIDE
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
NSC
64198
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
EVMPD
SUB07071MIG
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
CHEBI
4495
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
NCI_THESAURUS
C428
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
NSC
76130
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
FDA UNII
O5CB12L4FN
Created by admin on Mon Mar 31 17:50:23 GMT 2025 , Edited by admin on Mon Mar 31 17:50:23 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CARBONIC ANHYDRASE 1
TARGET -> INHIBITOR
CARBONIC ANHYDRASE 2
TARGET -> INHIBITOR
Related Record Type Details
Structure of DIAZOXIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966